KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Profit After Tax (2016 - 2025)

Regeneron Pharmaceuticals has reported Profit After Tax over the past 17 years, most recently at $844.6 million for Q4 2025.

  • Quarterly results put Profit After Tax at $844.6 million for Q4 2025, down 7.97% from a year ago — trailing twelve months through Dec 2025 was $4.5 billion (up 2.09% YoY), and the annual figure for FY2025 was $4.5 billion, up 2.09%.
  • Profit After Tax for Q4 2025 was $844.6 million at Regeneron Pharmaceuticals, down from $1.5 billion in the prior quarter.
  • Over the last five years, Profit After Tax for REGN hit a ceiling of $3.1 billion in Q2 2021 and a floor of $722.0 million in Q1 2024.
  • Median Profit After Tax over the past 5 years was $1.1 billion (2021), compared with a mean of $1.3 billion.
  • Biggest five-year swings in Profit After Tax: soared 245.36% in 2021 and later crashed 72.5% in 2022.
  • Regeneron Pharmaceuticals' Profit After Tax stood at $2.2 billion in 2021, then crashed by 46.29% to $1.2 billion in 2022, then decreased by 3.13% to $1.2 billion in 2023, then fell by 20.86% to $917.7 million in 2024, then decreased by 7.97% to $844.6 million in 2025.
  • The last three reported values for Profit After Tax were $844.6 million (Q4 2025), $1.5 billion (Q3 2025), and $1.4 billion (Q2 2025) per Business Quant data.